Hartree Partners, Hudson Technologies director, buys $1.3M in shares

Hartree Partners, a 10% owner and director of Hudson Technologies, bought 300,000 shares for approximately $1.31 million from October 29 to November 2, bringing its beneficial ownership to 5,648,517 shares; HDSN was trading at $4.23, near its $4.10 52-week low. The purchases come after Q3 2026 EPS of $0.05 and revenue of $59.4 million missed estimates of $0.21 and $74.98 million, respectively, amid lower HFC prices and weaker demand. Canaccord cut its price target from $8 to $7 while maintaining a Buy rating.

Analysis

The insider buying is a modest alignment signal, not evidence that fundamentals have turned: the buyer is already a large owner, and the ownership disclaimer limits what can be inferred about its economic exposure. The more important near-term mechanism is estimate risk. A sharp revenue and EPS miss tied to weaker HFC pricing and demand can prompt further forecast cuts; a better-than-internal-plan gross margin does not offset that risk unless it proves durable as volumes and realized prices evolve.

Over 1–3 months, watch realized refrigerant pricing, sales volumes, and management’s next guidance for evidence the downturn is stabilizing. The structural case is that refrigerant reclamation and regulatory phase-down dynamics may support value over time, but timing and inventory/pricing pressure can overwhelm that benefit in the near term. A break below the prior low would weaken the stabilization thesis; sustained pricing and volume improvement would strengthen it. The analyst target and third-party fair-value estimate are not independent evidence of a floor. No compelling signal here to short aggressively or buy solely on the insider activity.

Key Decisions for Investors

• Do not chase HDSN on the insider purchases. Treat them as a secondary signal until operating results confirm stabilization.
• Keep HDSN on a watchlist; consider a small, staged long only after evidence of improving HFC realizations or volume and a price that holds above the recent low. Define risk around a decisive close below that low.
• Before adding, verify the next quarter’s pricing, volume, gross-margin trend, and guidance. Further estimate reductions or continued weakness in both price and demand would falsify the recovery thesis and argue against the position.
• Avoid using the analyst target or vendor fair-value figure as a standalone valuation anchor; no strong trade is warranted without a clearer earnings inflection.